A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia
- 1 August 2014
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 134 (2) , 274-280
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group studyGynecologic Oncology, 2012
- Contemporary management of endometrial cancerThe Lancet, 2012
- Recent advances in systemic therapy for advanced endometrial cancerCurrent Opinion in Oncology, 2011
- What is the Role of Chemotherapy in Endometrial Cancer?Current Oncology Reports, 2011
- Treatment options for advanced endometrial carcinomaGynecologic Oncology, 2010
- Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-PJournal of Clinical Oncology, 2009
- Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group studyGynecologic Oncology, 2003
- A Phase II Trial of Topotecan in Patients with Advanced, Persistent, or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group StudyGynecologic Oncology, 2002
- Phase II Trial of the Pegylated Liposomal Doxorubicin in Previously Treated Metastatic Endometrial Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2002